Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01069328 · ClinicalTrials.gov registry record · Phase 1
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01069328 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 33 participants.
The verdict
NCT01069328, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
Interventions
- DRUG Bevacizumab
- DRUG Nexavar (Sorafenib, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01069328
The ClinicalTrials.gov registry entry for NCT01069328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01069328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01069328 about?
NCT01069328 is a clinical study titled "Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)". To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
What is the current status of trial NCT01069328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2006-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01069328?
The interventions under investigation include: Bevacizumab (DRUG), Nexavar (Sorafenib, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT01069328?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.